Introduction. While preoperative chemotherapy is frequently utilized before resection of non-neuroendocrine liver metastases, patients with resectable neuroendocrine liver metastases typically undergo surgery first. FAS is a cytotoxic chemotherapy regimen that is associated with substantial response rates in locally advanced and metastatic pancreatic neuroendocrine tumors. Methods. All patients who underwent R0/R1 resection of pancreatic neuroendocrine liver metastases at a single institution between 1998 and 2015 were included. The outcomes of patients treated with preoperative FAS were compared with those of patients who were not. Results. Of the 67 patients included, 27 (40.3%) received preoperative FAS, whereas 40 (59.7%) did not. Despite being associated with higher rates of synchronous disease, lymph node metastases, and larger tumor size, patients who received preoperative FAS had similar overall survival Although the clinical course of low-and intermediategrade pNETs is believed to be indolent, as many as 40% of patients with pNETs will develop neuroendocrine liver metastases (NELM) during their lifetime.
Conclusions. The use of FAS before liver resection is associated with improved OS compared with surgery alone among patients with advanced synchronous pancreatic neuroendocrine liver metastases.
Pancreatic neuroendocrine tumors (pNET) are heterogeneous in both their clinical presentation and behavior. 1 Although the clinical course of low-and intermediategrade pNETs is believed to be indolent, as many as 40% of patients with pNETs will develop neuroendocrine liver metastases (NELM) during their lifetime. 2 Although the presence of liver metastases is one of the strongest negative prognostic indicators in patients with pNET, surgical resection of NELM, when possible, is associated with a significant survival benefit. 3, 4 In fact, a meta-analysis reported a pooled median 5-year overall survival (OS) rate of 71% in patients who underwent liver resection and [ 95% experienced symptomatic relief. 5 Other liver-directed therapies include radiofrequency ablation, transarterial embolic therapy, and most recently, peptide receptor radionuclide therapy, but liver resection is typically associated with the best long-term outcomes and is considered the first choice for management of NELM. 6 Most patients with liver metastases of non-neuroendocrine origin receive multimodality therapy that includes systemic chemotherapy as a component of the treatment strategy. The purpose of preoperative chemotherapy include the potential to stimulate tumor downstaging, the opportunity to assess response of the tumor to therapy, and to ensure stable tumor biology before undergoing major surgery. In patients with advanced colorectal liver metastases, for example, the combination of perioperative 5-flourouracil (5-FU)-based chemotherapy and liver resection at experienced centers is associated with excellent survival outcomes. 7, 8 Furthermore, perioperative systemic chemotherapy is frequently used before to liver resection in other cancers as well to select for patients with disease stability and improve survival rates. 9 However, a similar role for preoperative chemotherapy in NELM secondary to pNETs has not been previously reported.
Streptozocin was the first therapy approved for patients with advanced or symptomatic pNET. 10 Since then, investigators have reported on its improved efficacy when combined with 5-FU and doxorubicin. 11, 12 At the University of Texas MD Anderson Cancer Center, we have observed response rates of more than 40% among patients with locally advanced and metastatic pNET when treated with combination 5-fluorouracil, doxorubicin, and streptozocin (FAS). 13, 14 Recently, we evaluated our experience with preoperative FAS in patients with non-metastatic locally advanced well-differentiated pNETs and found that FAS was infrequently associated with significant tumor downstaging suggesting differential effects of chemotherapy on the primary versus metastatic tumors. 15 The role of preoperative FAS in patients with advanced NELM, with or without the primary pNET in situ, has not been previously explored. Within this context, we set out to evaluate the influence of preoperative FAS on the outcomes of patients with pancreatic NELM who underwent liver resection.
MATERIALS AND METHODS

Patient Selection
The Institutional Review Board of MD Anderson Cancer Center approved this retrospective study (PA17-0318). From a prospectively maintained database, we included all patients who underwent liver resection for NELM of pancreatic origin between January 1998 and December 2015, with follow-up through March 2017. Patients who underwent macroscopically positive resection (n = 3) were excluded.
Next, we evaluated all patients with advanced metastatic pNET who received treatment with FAS at our institution without undergoing hepatectomy. After excluding patients with extrahepatic metastases (n = 110) and those in whom macroscopically negative resection was not possible using modern hepatectomy strategies (n = 74), we identified a cohort of patients with potentially resectable NELM treated non-operatively with FAS and other therapies. All patients were C 18 years of age, had an Eastern Cooperative Group (ECOG) performance status of 0 to 1 with adequate hepatic, renal, and bone marrow function for potential liver resection.
Chemotherapy Regimen
FAS included an intravenous 400 mg/m 2 bolus of 5-FU and an intravenous 400 mg/m 2 bolus of streptozocin on days 1-5 as well as 40 mg/m 2 intravenous bolus of doxorubicin on day 1 with each cycle repeated every 28 days. The typical objective was treatment to maximal radiographic response, unacceptable toxicity, or patient intolerance.
14,15 Drug toxicities were monitored closely, with modifications and dose adjustments made as necessary for laboratory abnormalities (hyperbilirubinemia at the beginning of therapy or uncontrolled diabetes mellitus in the case of streptozocin); reduction in cardiac function (for doxorubicin) or any other grade 3 or 4 toxicities while on therapy. Occasionally, grade 1 or 2 toxicities led to dose reduction or to delay of the treatment. Following preoperative FAS chemotherapy, patients were restaged with CT or MRI. Tumor markers, bone scans, and somatostatin scintigraphy were obtained as needed and surgical resection was offered to those for whom margin-negative hepatic resection was considered achievable. Adjuvant systemic therapy was not routinely administered following surgical resection.
Review of Patient Records
The following factors were retrieved from the database: sex, age, body mass index, number of tumors, largest diameter of the tumor, distribution, lymph node metastasis, clinical stage, tumor grade, Ki-67 index (from liver metastasis), extent of hepatectomy, and long-term outcomes. OS was measured from the date of initial treatment (preoperative chemotherapy or surgical resection) until the date of death or last follow-up. Recurrence-free survival (RFS) was measured from the date of surgery until the date of radiographic detection of recurrence or last follow-up. Laboratory data, tumor number, and size were evaluated before FAS chemotherapy or surgery when patients were treatment-naive. Clinical stage was based on the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual. 16 Major resection was defined as hepatic resection, including three or more segments. Postoperative morbidities were reviewed based on Clavien-Dindo classification. 17 Complications classified as grade III or higher were defined as major.
Statistical Analyses
First, the clinicopathologic characteristics and survival outcomes of patients who received FAS before undergoing liver resection were compared with those of patients who underwent liver resection without preoperative FAS. Next, we performed a subset analysis of only patients who presented with synchronous liver metastases with primary pNETs in situ. Finally, the patients who underwent surgical resection with or without preoperative FAS were compared to a cohort of patients with potentially resectable liver metastases who received FAS without surgical resection.
Continuous variables were compared using the Wilcoxon rank-sum test, whereas categorical variables were compared using the v 2 test. Survival curves were generated using the Kaplan-Meier method, and differences between curves were evaluated with the log-rank test. All test were two-side, and p \ 0.05 was considered significant. Statistical analyses were performed with JMP software (version 12.1.0; SAS Institute Inc., Cary, NC).
RESULTS
Of the 67 patients with pancreatic NELM who underwent surgical resection between 1998 and 2015, 27 (40.3%) received preoperative FAS, whereas 40 (59.7%) did not. Of the 40 patients who did not receive preoperative FAS, 31 received upfront surgical resection, whereas 9 received another preoperative chemotherapy regimen (doxorubicinstreptozocin, 5-FU-gemcitabine, 5-FU-streptozocin, bleomycin-epirubicin-cisplatin, 5-FU-oxaliplatin-bevacizumab, temozolomide-capecitabine, temozolomide, paclitaxel, and irinotecan-cisplatin) followed by surgical resection. The median number of cycles of FAS administered before surgery was four (range 2-13). Seventeen patients (63.0%) experienced a partial response (PR) according to RECIST criteria ( Fig. 1) , whereas eight (29.6%) had stable disease and two (7.4%) had progressive disease. Among the 16 patients who had synchronous disease and experienced a PR in their liver metastases, only 7 (43.8%) demonstrated a PR in their primary pNET, while 9 (56.3%) had stable disease. Of the 27 patients who received FAS before surgery, 22 (81.5%) were resectable before preoperative chemotherapy and 5 (18.5%) were initially unresectable but became resectable after preoperative FAS. (Fig. 2) .
Among the 46 patients who presented with synchronous liver metastases along with an intact primary pNET, 26 underwent preoperative FAS before surgical resection, whereas 20 did not. Resections were synchronous in 35 (76.1%) and staged in 11 (23.9%). The clinicopathologic and operative characteristics of the two groups were similar except patients who received preoperative FAS were more likely to have a higher primary tumor T-stage (Supplementary (Fig. 3) .
Twenty-four patients were retrospectively identified as having potentially resectable pancreatic NELM but were treated with FAS and did not undergo liver resection (Table 1) . For all patients, FAS was first-line therapy and the median number of cycles received was five (range 1-13). The majority of patients (79.2%) had their primary tumor in situ. Patients who received FAS alone were less likely to have a solitary liver metastasis compared with patients who underwent FAS and surgery as well as surgery alone (12.5% vs. 44.4% vs. 40.0%, p \ 0.05). The median size of the largest metastasis was 3.5 (range 1.0-8.2) cm. Reasons for not undergoing surgical resection were absence of documented consultation with a hepatobiliary surgeon (58.3%), locally advanced primary pNET (12.5%), concern for older age or comorbidities (8.3%), progressive disease on therapy (4.2%), complete radiographic response (4.2%), and reasons not ascertainable by retrospective review of the medical chart (16.7%). Seven of 24 patients' (29.2%) liver metastases exhibited a PR following FAS. Among these seven patients, the primary pNET demonstrated a PR in two patients (28.6%) and SD in five patients 
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DISCUSSION
Although the management of resectable liver metastases in other malignancies often involves a short course of preoperative systemic chemotherapy to ensure disease stability, allow for potential tumor downstaging, and monitor the response to therapy, most patients with resectable NELM are offered upfront surgical resection. This may be related to the lack of data available on effective neoadjuvant treatment strategies for patients with NELM. Our study, albeit retrospective, represents one of the first to demonstrate the potential efficacy of a preoperative regimen for patients with potentially resectable pancreatic NELM who present with advanced disease. Specifically, our study has several pertinent findings. First, among patients included in this retrospective study who underwent resection, the response rate of pancreatic NELM to FAS was approximately 63%. Second, despite more aggressive clinical and biological characteristics, patients who underwent FAS before surgical resection had similar OS and RFS compared with patients who underwent surgery first without any increase in the incidence of major postoperative complications. Third, among patients with synchronous liver metastases, preoperative FAS was associated with a significant OS and RFS survival benefit. Finally, compared with patients treated with FAS alone for potentially resectable liver metastases, those who underwent liver resection after FAS had significantly better OS. The combination of streptozocin with doxorubicin is a common therapeutic regimen for patients with metastatic or advanced pNET based on the results of a series of randomized, controlled trials from the Eastern Cooperative Oncology Group. 11, 12 However, our institution has preferentially used the triple chemotherapy regimen of 5-FU, doxorubicin, and streptozocin, which has resulted in response rates as high as 55% in previous reports. 14 Moreover, these responses are fairly durable with the median duration of tumor response nearly 10 months in one series. 13 Interestingly, the response rate in this cohort of patients with metastatic disease confined to the liver and eventually selected for liver resection was an impressive 63%. This is especially striking given our recent finding that FAS was associated with only a partial response rate of 7% when used as preoperative therapy for locally advanced primary pNET. 15 Even in the current study, the primary pNET demonstrated a response to FAS less often than the liver metastases. Why this treatment strategy appears more efficacious for the hepatic disease is unknown, but given the prognostic importance of liver metastases (and their resectability) on survival in patients with pNET, identification of an effective treatment regimen that facilitates surgical resection is critically important. 5, 18 Although data are limited on the use of preoperative chemotherapy for pNETs, there are increasing reports on the use of preoperative PRRT for locally advanced or unresectable PNETs. 15, [19] [20] [21] [22] [23] Even fewer reports are available on the use of preoperative therapy for NELM, although clearly there is interest in identifying effective neoadjuvant treatment strategies for this unique population of patients. [24] [25] [26] It is noteworthy that most of the previously published case reports and small case series' goal was facilitation of resectability, whereas our results with preoperative FAS in this study suggest the potential for improved OS and RFS, especially in those patients with synchronous disease.
Although the results of this study are novel and potentially impactful, they should be interpreted within the context of their limitations. First, this is a single-institution, retrospective study in which treatment decisions were not made randomly. Because of its retrospective nature, we were unable to reliably identify those patients who initiated FAS with preoperative intent but failed to undergo liver resection. Similarly, we were unable to assess via retrospective chart review whether patients in the FAS alone group were treated with a preoperative intent (but failed to undergo surgery) or were being treated with definitive chemotherapy. This inability to define a true ''denominator'' allows for a selection bias in the analysis of the final group of patients who received FAS prior to surgery. Second, while we retrospectively confirmed that the FAS alone patients were anatomically resectable to match grossly the tumor characteristics to other cohorts, other equally important factors affecting resectability (e.g., patient comorbidities or performance status, tumor biology, patient preference, etc.), and unmeasured factors could not be retrospectively assessed but likely differed between groups. Third, some patients in the nonpreoperative FAS groups received alternate preoperative chemotherapy regimens. However, the purpose of the study was to evaluate the impact of preoperative FAS not any preoperative therapy, and the inclusion of these patients in the control group might be hypothesized to minimize, not amplify, any survival differences. Fourth, this study does not have pathologic data available to measure tumor response to therapy. Finally, given its retrospective nature, this study did not assess toxicities of the preoperative regimen, although this would be expected to be consistent with previous reports. 13 
CONCLUSIONS
Pancreatic NELM demonstrated excellent response rates to FAS. The use of FAS before liver resection was associated with improved OS compared with surgery alone among patients with synchronous metastases as well improved OS compared with FAS alone without surgical resection. Patients with pancreatic NELM should be evaluated in a multidisciplinary setting where multimodality treatment decisions can be made collectively before treatment sequencing decisions are finalized. Preoperative FAS could be considered for patients with advanced synchronous pancreatic NELM.
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